Pipeline
in vivo CAR-M
In vivo CAR-M is designed to program macrophages directly within the patient using P-LNP to deliver CAR-encoding mRNA. Resulting CAR-expressing macrophages recognize and eliminate tumor cells through phagocytosis while activating a broader anti-tumor immune response. By leveraging the natural ability of macrophages to infiltrate tumors, kill tumor cells, and remodel the immunosuppressive tumor microenvironment, this program may offer advantages over CAR-T therapies in solid tumors.
